76.6%
Rituximabmycophenolate mofetilcyclophosphamideneonatal Fc receptor blockerscomplement inhibitorsChronic inflammatory demyelinating polyradiculoneuropathy (CIDP)immunoglobulin therapyEuropean Academy of Neurology/Peripheral Nerve Societyplasmapheresisimmunotherapy
…pproximately 15% remain refractory to all treatment modalities. Rituximab, mycophenolate mofetil and cyclophosphamide are of therapeutic …